Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Inflammatory tolerance is the down-regulation of inflammation upon repeated stimuli, which is well-established to occur in peripheral immune cells. However, less is known about inflammatory tolerance in the brain although it may provide an important protective mechanism from detrimental consequences of prolonged inflammation, which appears to occur in many psychiatric and neurodegenerative conditions. Array analysis of 308 inflammatory molecules produced by mouse primary astrocytes after two sequential stimulations with lipopolysaccharide (LPS) distinguished three classes, tolerant, sensitized and unaltered groups. For many of these inflammatory molecules, inhibition of glycogen synthase kinase-3 (GSK3) increased tolerance and reduced sensitization. Focusing on LPS-tolerance in interleukin-6 (IL-6) production, we found that microglia exhibited a strong tolerance response that matched that of macrophages, whereas astrocytes exhibited only partial tolerance. The astrocyte semi-tolerance was found to be regulated by GSK3. GSK3 inhibitors or knocking down GSK3 levels promoted LPS-tolerance and astrocytes expressing constitutively active GSK3 did not develop LPS-tolerance. These findings identify the critical role of GSK3 in counteracting IL-6 inflammatory tolerance in cells of the CNS, supporting the therapeutic potential of GSK3 inhibitors to reduce neuroinflammation by promoting tolerance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · cited 1×
“GSK3 is a highly conserved Ser/Thr protein kinase that is constitutively active (Cohen and Frame, 2001, Doble and Woodgett, 2003, Jope and Johnson, 2004).”
BackgroundGene-specific control of inflammation by TLR-induced chromatin modifications
Foster, S. L., Hargreaves, D. C., & Medzhitov, R. (2007) · Nature · doi:10.1038/nature05836 · Cited by 1,344
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321 · cited 2×
“…GSK3 regulated adaptive responses to repeated stimulation with LPS, during the first incubation, additional cells were treated with 20 mM lithium to fully inhibit GSK3 (Klein and Melton, 1996, Stambolic et al., 1996), followed by thoroughly washing out the lithium before the second exposure to LPS.”
MethodRegulation of innate immune responses in the brain
Rivest, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2565 · Cited by 843 · cited 1×
“This may be due to the long lifetimes of neurons and likely partially underlies the barriers that evolved to isolate the brain from the life-sustaining peripheral inflammatory responses that are required for pathogen resistance (Rivest, 2009).”
BackgroundSchneider, D. S., & Ayres, J. S. (2008) · Nature Reviews Immunology · doi:10.1038/nri2432 · Cited by 783
Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis
McManus, E. J., Sakamoto, K., Armit, L. J., Ronaldson, L., Shpiro, N., Marquez, R., & Alessi, D. R. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600633 · Cited by 594 · cited 2×
“GSK3 is predominantly regulated by inhibitory phosphorylation of its two isoforms, serine-9 in GSK3β and serine-21 in GSK3α, which is abrogated in GSK3 knockin mice that express serine-to-alanine mutations in both isoforms (McManus et al., 2005).”
BackgroundInterleukin-6 Covaries Inversely with Hippocampal Grey Matter Volume in Middle-Aged Adults
Marsland, A. L., Gianaros, P. J., Abramowitch, S. M., Manuck, S. B., & Hariri, A. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.016 · Cited by 348 · cited 1×
“We focused on the regulation of tolerance in IL-6 production by GSK3 because IL-6 has been associated with several neurodegenerative and psychiatric diseases, including impairing higher functions such as cognition (Campbell et al., 1997, Marsland et al., 2008, Dugan et al., 2009).”
BackgroundYuskaitis, C. J., & Jope, R. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.10.014 · Cited by 240 · cited 1×
“Regardless of the mechanism, it is evident that inhibiting GSK3 not only reduces initial production of inflammatory molecules in the periphery and the brain (Martin et al., 2005, Beurel and Jope, 2009b, Yuskaitis and Jope, 2009), it also promotes IL-6 tolerance to repeated inflammatory stimuli.”
BackgroundBull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228 · cited 1×
“…is involved in many neuroinflammatory conditions and promotion of tolerance to LPS would provide a mechanism to reduce neuroinflammation (Cerciat et al., Lee et al., Sironi et al., 1993, Bull et al., 2009), we examined in greater detail the regulation by GSK3 of LPS-tolerance in IL-6 production.”
Background
Cited by
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536
“in the cleavage of the amyloid- protein precursor (A PP) by its action on presenilin or peptidylprolyl cis/trans isomerase [10,11], as well as in other neurodegenerative processes, such as inflammation [12], apoptosis [13], impaired axonal transport [14], reduced synaptic plasticity [15], and regulation of long-term p…”
BackgroundTreatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329
“GSK-3 also has an important role in other key features of AD neuropathology, such as inflammation [10], apoptosis [11], impaired axonal transport [12], reduced synaptic plasticity [13], and inhibition”
Maes, M., Fišar, Z., Medina, M., Scapagnini, G., Nowak, G., & Berk, M. (2012) · Inflammopharmacology · doi:10.1007/s10787-011-0111-7 · Cited by 325
A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy
Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320
Dionísio, P. A., Amaral, J. D., Ribeiro, M. F., Lo, A. C., D'Hooge, R., & Rodrigues, C. M. P. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.034 · Cited by 127
Metadata
- Authors
- Beurel, E., & Jope, R. S.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 169
- Issue
- 3
- Pages
- 1063-1070
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2023215882
- Cited by
- 59
- References
- 13
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes. https://app.cochat.ai/papers/10.1016/j.neuroscience.2010.05.044
- The paper
- Beurel, E., & Jope, R. S. (2010). Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes. Neuroscience. https://doi.org/10.1016/j.neuroscience.2010.05.044
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.